Can a therapy without living cells help repair the eye? That is the premise behind the Nucelion Pandorum partnership, reported on 28 October 2026. Nucelion Therapeutics, a Bharat Biotech subsidiary in Hyderabad that makes cell and gene therapy products for others, will support process development and manufacturing for two investigational programmes from Pandorum Technologies of Bengaluru. The programmes target advanced keratopathy and wet age-related macular degeneration and are backed by an Indian government scheme. This article explains the science in plain language, what stage the projects are at and why manufacturing is a critical, often overlooked, step.
Key takeaways: the Nucelion Pandorum partnership and exosome therapy
- Both programmes use Pandorum’s cell-free approach based on designer exosomes and are investigational.
- The keratopathy project is moving toward clinical evaluation; the wet AMD project is preclinical.
- Nucelion will provide GMP process development and manufacturing support.
- The planned outlay is ₹16.97 crore, with up to ₹8 crore from the PRIP scheme.
- No clinical data, timelines or approvals have been announced.
What cell-free regenerative medicine means in the Nucelion Pandorum partnership
Regenerative medicine seeks to repair or replace damaged tissue. Many approaches use living cells, which are complex to make and store. A cell-free approach uses products released by cells instead. Exosomes are small packages of proteins, fats and genetic material that cells release to communicate with each other. Developers study whether exosomes taken from, or designed after, particular cells can reduce inflammation and scarring or encourage repair. Pandorum describes its designer exosomes as tuned to address inflammation, fibrosis and vascular problems. The announcement does not give technical detail, and this explanation is general background.
The eye conditions behind the Nucelion Pandorum partnership
Advanced keratopathy is serious damage to the cornea, the transparent dome at the front of the eye, where scarring and swelling can cloud vision. Wet age-related macular degeneration affects the macula, the part of the retina used for sharp central vision, when abnormal blood vessels leak. The US National Eye Institute describes AMD on its AMD information page. The two diseases differ, and the partnership treats them as separate programmes with separate evidence needs.
Why manufacturing matters in the Nucelion Pandorum partnership
Biological products are harder to make consistently than simple chemicals. Every batch must be shown to match the last so that trial results mean something, and regulators inspect the process as closely as the product. Good manufacturing practice, or GMP, sets the standards. Nucelion says its contribution is turning product requirements into reproducible processes with quality built in. A cell-free product still needs careful control of its source cells, purification, characterisation and storage. The announcement does not describe how these will be done. Nucelion’s parent group is described at bharatbiotech.com.
How funding works in the Nucelion Pandorum partnership
The projects are supported by the Promotion of Research and Innovation in Pharma-MedTech scheme, with up to ₹8 crore of the ₹16.97 crore planned outlay coming from it, about 47% by our own arithmetic. Government policy information is available from the Department of Pharmaceuticals. Public co-funding can lower the risk for early-stage developers, but it does not indicate that a therapy will work. See also our Life Science coverage.
How exosome therapies are typically evaluated, beyond the Nucelion Pandorum partnership
Evaluating a cell-free product differs from testing a conventional drug. Developers usually need to show what the preparation contains, how consistently it can be produced, and how its biological activity can be measured in a laboratory assay that predicts effect. Safety studies in animals come first, followed by small human studies that look for tolerability before any question of benefit. For eye products, local delivery matters, because the cornea and retina are accessible but sensitive. None of these steps has been reported for Pandorum’s programmes, and this paragraph describes the general path and not their status.
Questions the Nucelion Pandorum partnership leaves open
Several scientific questions remain. What exactly is in each product, and how is it characterised? What animal or early human data support the keratopathy programme as it nears clinical evaluation? Which route of administration is planned for each eye disease? What are the safety signals? How will potency be measured so that each batch is comparable? And where will the material be made? The announcement does not address them, and we do not assume answers. Regulators will expect all of these before approving clinical studies.
Market data from Acumen Research and Consulting
Acumen Research and Consulting’s Macular Degeneration Treatment Market report puts the global market at USD 9.1 billion and USD 17.4 billion by 2032, a CAGR of 7.6%, with wet AMD about 80% of the market in 2023 and Asia Pacific the fastest-growing region at over 8.4%. The page is inconsistent on its base year and shows a 2019 updated date, so the figures are estimates. They describe current treatments and not investigational exosome products.
Timeline of the Nucelion Pandorum partnership
- 28 October 2026: partnership reported.
- Not dated: first clinical-grade batches and clinical evaluation of the keratopathy programme.
General background: moving from lab to clinic
A new therapy typically moves from laboratory work to animal studies, then to safety trials in people and later to larger efficacy trials. Most candidates do not reach approval, which is why early-stage announcements are best read as progress on development and not proof of benefit.
Our analysis of the Nucelion Pandorum partnership
In our assessment, the Nucelion Pandorum partnership is a credible step in building India’s capacity for advanced therapies, because it pairs a developer with a specialist manufacturer. It is not evidence that the therapies work. The decisive information will be data from clinical studies.
What is not disclosed in the Nucelion Pandorum partnership
- Preclinical or clinical results.
- Regulatory filings and timelines.
- Funding for the part not covered by PRIP.
- Manufacturing location and scale.
Risks and caveats
Both therapies are investigational; clinical use depends on regulatory approval. Our explanation of exosomes is general background. This article is news reporting and not medical advice.
What to watch next
- Clinical trial registrations.
- Published preclinical data.
- Manufacturing milestones.
FAQ
Are these treatments available?
No. They are investigational.
What is a designer exosome?
The announcement does not define it; exosomes are small cell-released packages that developers try to engineer.
Who makes the product?
Nucelion will provide process development and manufacturing support.
How we reported this: we relied on the companies’ announcement as relayed in press reports, government and eye-health information pages and the Acumen Research and Consulting report cited above. Our calculation is labelled. Last updated 29 October 2026. This is news reporting and not advice.
